BREAKING
Home » Posts Tagged "Ibrexafungerp"

Vaginal Yeast Infections treatment, Oral Ibrexafungerp, receives FDA Acceptance and Priority Review of New Drug Application

By

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration...

Candida: NDA submitted to the FDA for antifungal drug representing a new class in over 20 years

By

Biotechnology company, SCYNEXIS, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral ibrexafungerp for the treatment of vulvovaginal...

Vaginal Yeast Infection treatment: SCYNEXIS announces positive top-line results from its second pivotal Phase 3 Study of Oral Ibrexafungerp

By

SCYNEXIS, Inc. announced this week positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment...

Aspergillosis, a new kind of antifungal drug and World Aspergillosis Day

By

Today is World Aspergillosis Day, a day to raise awareness about a fungal infection that kills more than one million people globally each year. Joining me now to talk about aspergillosis, a new kind of...

Antifungal drug, Ibrexafungerp, for the treatment of vaginal yeast infection, progresses to late stage development

By

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global...